CPS Surgical Management of Kidney Stones (2016)

Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The purpose of this Guideline is to provide a clinical framework for the surgical management of patients with kidney and/or ureteral stones.

Target Audience

  • Resident
  • Urologist

Learning Objectives

After completion of this activity, participants will be able to:

  1. Interpret and explain the appropriate diagnosis, prevention and treatment of the related guideline.
  2. Perform appropriate methods of evaluation and management according to the guideline.
  3. Analyze the risks and benefits for treatment according to the guideline.
  4. Integrate AUA guidelines into clinical practice.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
11/01/2016
Course expires: 
11/01/2019
Rating: 
0

Faculty
Faculty Disclosures

NameCompanyRole
Michael Eric Lipkin ,MDBoston ScientificConsultant or Advisor, Meeting Participant or Lecturer
 LumenisMeeting Participant or Lecturer
 OlympusConsultant or Advisor
Nicole Miller ,PANothing to disclose
Vernon M. Pais Jr.,MDClinical NephrologyHealth Publishing
Ojas Shah, MDTaris Biomedical, IncScientific Study or Trial
 Watson PharmaceuticalScientific Study or Trial
 Boston ScientificConsultant or Advisor, Meeting Participant or Lecturer
 Cook UrologicalConsultant or Advisor, Meeting Participant or Lecturer
 CovidienConsultant or Advisor
 Metropolitan Lithotriptor/Allied HealthInvestment Interest
 Karl StorzMeeting Participant or Lecturer
 LumenisConsultant or Advisor, Meeting Participant or Lecturer
 MD AgreeInvestment Interest
 ElsevierHealth Publishing
 American Urological AssociationMeeting Participant or Lecturer, Other
 Bristol Myers SquibbInvestment Interest
 NJ Kidney Stone CenterInvestment Interest
 Glaxo Smith KlineInvestment Interest
 NovartisInvestment Interest


Planner Disclosures
Education Council

Timothy Charles Brand, MDNothing to disclose 
Peter Robert Carroll, MD, MPHNIHScientific Study or Trial
 Department of DefenseScientific Study or Trial
 Myriad GeneticsScientific Study or Trial
 AUA UpdateLeadership Position
 Genomic HealthScientific Study or Trial
Sam S. Chang, MDastellasConsultant or Advisor
 NIHScientific Study or Trial
 GLGConsultant or Advisor
 BayerConsultant or Advisor
 JanssenConsultant or Advisor
Shelby EnglertNothing to disclose 
Matthew Thomas Gettman, MDNothing to disclose 
Christina GiffinNothing to disclose 
Inderbir Singh Gill ,MD, M.Ch.EDAPConsultant or Advisor
William C. Hulbert Jr. MDNothing to disclose 
Douglas A. Husmann MDNothing to disclose 
Brant Inman, MD, MS, FRCSCDendreonScientific Study or Trial
 Abbott LaboratoriesScientific Study or Trial
 Genentech IncScientific Study or Trial
 Combat MedicalConsultant or Advisor
 FKD TherapiesScientific Study or Trial
 AstraZenecaConsultant or Advisor
Mark L. Jordan MD,FACSNothing to disclose 
Hari K. Koul, MSC,PHDNovartis PharmaceuticalsConsultant or Advisor
 Urologic ResearchLeadership Position
 PLOS oneLeadership Position
 OMICS groupLeadership Position
 Open Access PublishingLeadership Position, Health Publishing
Martin A. Koyle MDNothing to disclose 
John Stephen Lam MDNothing to disclose 
Gary Evan Lemack ,MDAstellasConsultant or Advisor, Meeting Participant or Lecturer
 AllerganConsultant or Advisor, Meeting Participant or Lecturer
 SophirisScientific Study or Trial
 MedtronicConsultant or Advisor
Yair Lotan ,MDabbottScientific Study or Trial
 DanoneConsultant or Advisor, Scientific Study or Trial
 CepheidScientific Study or Trial
 Pacific EdgeScientific Study or Trial
 FKDScientific Study or Trial
 MDxHealthConsultant or Advisor
 biocancellScientific Study or Trial
 Genomic HealthScientific Study or Trial
 GenomeDx Biosciences IncScientific Study or Trial
 photocureScientific Study or Trial
Manoj Monga, MDFortecOther
 endourology societyLeadership Position
Victor William Nitti MDAstellasHealth Publishing, Scientific Study or Trial
 AllerganHealth Publishing, Scientific Study or Trial
 Serenity PharmeuticalsInvestment Interest
 Cook MyositeScientific Study or Trial
Christopher Porter, MDGenomic HealthConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Gail S. Prins PhDNothing to disclose 
Jay D. Raman, MDAmerican Kidney Stone ManagementInvestment Interest
Lee Richstone, MDNothing to disclose 
Heather Schultz, NPSUNAMeeting Participant or Lecturer
Karl-Dietrich Sievert ,MD, PhDAMSMeeting Participant or Lecturer
 MedtronicsMeeting Participant or Lecturer, Scientific Study or Trial
 AllergenConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
 NeotractMeeting Participant or Lecturer
Joseph A. Smith Jr.,MDNothing to disclose 
Edouard John Trabulsi, MDGenomeDxConsultant or Advisor

 

 

Method of Participation

Learners will participate in this interactive online educational activity by completing a pre-test, reading the AUA Guideline, complete the slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete each activity: 2.0 hours

Release Date: November, 2016
Expiration Date: November, 2019

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the product prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Privacy and Confidentiality Policy

www.auanet.org/education/confidentiality-statement.cfm

Contact Information

American Urological Association
Office of Education
1000 Corporate Blvd
Linthicum, MD 21090

Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800

CME Information

For all inquiries regarding CME credit email: education@AUAnet.org

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.